Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AMLShai Shimony, Maximilian Stahl, R. Coleman Lindsley et al.|Leukemia|2024Cited by 30
Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid LeukemiaJustin Grenet, Pinkal Desai, Akriti Jain et al.|Blood|2021Cited by 20
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in <i>NPM1</i>-mutant AMLJan Philipp Bewersdorf, Maximilian Stahl, Shai Shimony et al.|Blood Advances|2024Cited by 12
Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxisCorinna La Rosa, Don J. Diamond, Ibrahim Aldoss et al.|American Journal of Hematology|2023Cited by 11
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort studyJan Philipp Bewersdorf, Maximilian Stahl, Shai Shimony et al.|American Journal of Hematology|2024Cited by 9